Clinical guide
Peptide therapy: research, risks, and clinical evaluation
In October 2026, HHS announced an interim enforcement policy addressing qualifying 503A compounding of six peptides. The policy is conditional and can change. It does not grant FDA approval to any of these drugs or establish that they treat a particular condition.
Editorial imageStart with the symptom or diagnosis, the evidence, and the risks. A licensed clinician can discuss established care and whether further evaluation makes sense. A prescription is never guaranteed.
What is peptide therapy?
Peptides are short chains of amino acids. The phrase “peptide therapy” covers many different substances and clinical situations; it does not describe one established treatment. Some peptide medicines have FDA-approved uses, while the six investigational substances discussed here do not have FDA-approved products for the promoted uses. Their evidence and safety questions must be assessed individually.
A search for a peptide name often starts with a real health concern: an injury, digestive symptoms, weight change, sleep trouble, or difficulty concentrating. The useful next step is to identify the condition and compare established care with the actual human evidence for a proposed peptide.
Explore the research
Six peptides. Six evidence questions.
Read what is known, what remains uncertain, and what to ask a clinician.
Featured research guide
BPC-157
What BPC-157 is, what the HHS compounding policy covers, and what to discuss with a licensed clinician before considering it.
Read the guide →
TB-500
Learn what TB-500 is, the limits of current evidence, and how the HHS interim 503A policy applies to qualifying compounding.
Read the guide →
KPV
A plain-language guide to KPV research, safety uncertainties, and the limits of the HHS interim compounding policy.
Read the guide →
MOTS-c
Understand MOTS-c research, limits of human evidence, and what the HHS interim 503A policy actually covers.
Read the guide →
Epitalon
Review Epitalon research, the limits of sleep and longevity claims, and the HHS interim compounding policy.
Read the guide →
Semax
Learn what Semax research shows, what remains uncertain, and how the HHS interim compounding policy is limited.
Read the guide →
Questions people ask next
BPC-157 side effects: what is known and unknown
A careful look at reported BPC-157 side effects, FDA safety concerns, and the gaps in human evidence before a clinical discussion.
TB-500 side effects: evidence and unanswered questions
Understand what is and is not known about TB-500 side effects, quality concerns, and the distinction from thymosin beta-4.
MOTS-c side effects: what human evidence can tell us
What human studies cannot yet tell us about MOTS-c side effects, metabolic claims, compounded product quality, and dosing.
BPC-157 vs TB-500: what the evidence actually compares
Compare BPC-157 and TB-500 evidence, safety uncertainties, and the HHS policy's single-ingredient condition without unsupported recovery claims.
BPC-157 benefits: what has been shown in people?
Examine BPC-157 benefit claims for injury recovery and digestive symptoms against the available human evidence and FDA safety concerns.
TB-500 benefits: what is the human evidence?
Review TB-500 recovery and wound-healing claims, the distinction from thymosin beta-4, and the limits of human evidence.
KPV peptide benefits: what is supported by human evidence?
Examine KPV inflammation and skin claims, the limits of preclinical research, and safety questions for human use.
MOTS-c benefits: what do human studies establish?
Review MOTS-c weight, exercise, and bone-health claims against human evidence and FDA's safety assessment.
Oral vs topical KPV: what changes with the route?
Understand how oral and topical KPV differ, the HHS bioavailability condition, and why neither route proves clinical benefit.
Semax vs Selank: what can be compared responsibly?
Compare Semax and Selank as distinct peptides, the limits of cognitive claims, and why the HHS interim policy does not cover a combined spray.
Can BPC-157 and TB-500 be combined?
Understand the single-ingredient condition for BPC-157 and TB-500, evidence gaps for blends, and questions for a clinician.
Semax for focus or ADHD: what does the evidence show?
Evaluate Semax focus and ADHD claims, the limits of human evidence, and why concentration problems need clinical assessment.
Epitalon for sleep and longevity: are the claims established?
Explore what Epitalon sleep and longevity research does and does not show for people considering a compounded product.
KPV side effects: what is known about human safety?
Learn why KPV side-effect rates are unknown, what FDA says about human safety data, and what to ask before considering an oral or topical formulation.
KPV vs BPC-157: what is different?
Compare KPV and BPC-157 research, proposed uses, safety gaps, and the HHS policy without unsupported treatment claims.
What the policy does and does not say
HHS describes limited enforcement discretion for certain state-licensed pharmacies, federal facilities, and licensed physicians when all policy conditions are met. Those include the specified ingredient and route, appropriate sourcing and testing, a single listed active ingredient, reporting and labeling, and a patient-specific prescription. Compounded drugs are not FDA approved.
Read the HHS policy ↗Common peptide therapy questions
Is peptide therapy safe?
Safety depends on the specific substance, formulation, route, and person. Human safety data for these six substances are limited. FDA has identified concerns for several, including possible immune reactions and peptide impurities.
Can I discuss peptide therapy online?
You can start with a clinical assessment. A licensed provider decides what evaluation or treatment is appropriate; an online assessment does not guarantee a prescription or access to any particular peptide.
How much does peptide therapy cost?
There is no single price for “peptide therapy.” Costs depend on the actual clinical service and, if appropriate and available, the specific treatment and pharmacy. Ask for the complete patient-facing price before making a decision.
Can these peptides be used for weight loss or muscle growth?
The six peptides in this guide do not have FDA-approved indications for those goals. In particular, MOTS-c weight claims have not been established for a compounded product. A clinician can discuss the diagnosis and established weight-management options.
Is there a different peptide therapy for women, men, or low energy?
These broad labels do not identify a treatment. The cause of fatigue or other symptoms, medical history, and evidence for the specific substance matter more than a general peptide category. No sex-specific benefit has been established for the six compounded products discussed here.
After researching a substance, review what the HHS policy permits and how to prepare for a clinical discussion.
No cost · No obligation
Discuss your goals with a clinician
Tell us what you are trying to address. A licensed clinician reviews your history and discusses appropriate options; no peptide or prescription is guaranteed.
Start an assessmentClinician evaluation required · No guaranteed prescription